Description
This product is a lypholized power needing reconstitution and sub q injection. PPP_GLP_Complete_Reconstitution__and_Dosing_Guide
Retatrutide is an experimental triple-hormone agonist developed by Eli Lilly that is currently undergoing Phase 3 clinical trials. Often referred to as a “super peptide,” it targets GLP-1, GIP, and glucagon receptors to significantly suppress appetite and boost metabolism, yielding unprecedented average weight loss results of up to 24% in trials.
How Retatrutide Works
Unlike current FDA-approved drugs like Semaglutide (which acts only on GLP-1) or Tirzepatide (which acts on GLP-1 and GIP), retatrutide targets three specific receptors:
- GLP-1 & GIP: Slow digestion, increase insulin secretion, and stimulate satiety in the brain.
- Glucagon: Helps break down fat cells and enhances energy expenditure.
Weight Loss and Clinical Efficacy
Trials have shown retatrutide to be one of the most powerful weight loss drugs ever studied.
- In Phase 2 trials, participants taking the highest doses for 11 months lost an average of 24% of their starting body weight.
- Some heavier patients in recent trials achieved weight loss results on par with gastric bypass surgery.
- Researchers are also actively studying its effectiveness for related health conditions like obstructive sleep apnea, knee osteoarthritis, and chronic low back pain.
Timeline and FDA Approval Status
As of 2026, retatrutide is not approved by the U.S. FDA for any condition. Phase 3 trials are actively underway. If trials are successful and results are submitted, formal FDA approval for weight loss could potentially follow in 2027
- All peptides which are for research only are labled accordingly. All sales are final. No refunds.
Reviews
There are no reviews yet.